Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer

OBJECTIVE: Foretinib (GSK1363089 or XL880), which is an oral multikinase inhibitor developed to primarily target the hepatocyte growth factor (HGF)/Met signaling pathway, has shown anti-tumor effects against some cancers in preclinical and clinical studies. RESULTS: HGF/Met signaling in endometrial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Kogata, Yuhei, Tanaka, Tomohito, Ono, Yoshihiro J., Hayashi, Masami, Terai, Yoshito, Ohmichi, Masahide
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5978264/
https://ncbi.nlm.nih.gov/pubmed/29854314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25232
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados